4 increases in the raltegravir arm compared to none in the elvitegravir arm. Patients Hesperidin of F More significantly affected by raltegravir can not have 3 or 4 degrees obtained Ht the concentration of aspartate aminotransferase that those affected do elvitegravir, seven patients had a student in the fourth year in the raltegravir arm in arm against each elvitegravir. Discussion The data of 48 weeks 96 weeks of our study show that the effi ciency of elvitegravir is not lower than in patients receiving raltegravir na Fs antiretroviral protease inhibitors ritonavirboosted and another agent. Effi ciency was independent non-inferior Ngig of the viral load or CD4 cell count or base by several subgroups of patients defined ned as the basic treatment. Adverse events and abnormal laboratory values were generally between treatment groups.
Although diarrhea was YM155 the hour Ufigsten assigned to persons reported elvitegravir had a corresponding number of patients in both treatment groups w diarrhea During the month fi RST after the start of the study medication. Erh Relationships Grade 3 or 4 liver enzymes were significantly more hours assigned More common in affected than those of elvitegravir with raltegravir significantly. Isolates with resistance mutations by elvitegravir or raltegravir, integrase, ph Phenotypic cross-resistance to two drugs was selected Hlt typical sequential prevented Age of one drug to another. We have developed U criteria for the treatment of substance in our study to ensure that each patient completely with a total capacity of two or three drugs YOUR BIDDING, including normal integrase inhibitor-treated fa distributed Is Feeder Llig.
In this construction, no individual would receive functional monotherapy and virological be formed failure.14 has secured 15 Our approach also means that the contribution of each case will integrase inhibitor randomized measurable. Other studies 11 18 13.16 Adding a drug to a basic treatment of three fully active drugs can not be more effi ciency in patients, na Fs antiretroviral treatment performed. The proportion of patients with viral suppression in this study is it Similar to previous studies in general and in those with a single active ingredient reported. In studies BENCHMRK reached 5.13, 62% of patients receiving raltegravir achieved HIV RNA levels below 50 copies per mL at week 48, and in the DUET studies, in view of 11.
12, 61% of individuals, however, etravirine virological suppression.19 DUET studies BENCHMRK and more background medications were allowed, and 20% 5 and 26% of the patients used the 11.12 m chtige drug enfuvirtide for the first time registration of fi. In the MOTIVATE studies 20, 46% of maraviroc had completely one Requests reference requests getting away. Were in the TITAN study, 21 in which a Similar high proportion of patients in our study in Resistance enrolled twoclass, reaching 60% of individuals with combined lopinavir and ritonavir treatment were viral suppression compared to 71% due to darunavir . In our study, the effi ciency of elvitegravir to viral suppression in patients with an active drug at week 48 Similar or h Ago as people with an active drug raltegravir-treated patients reported the background, 13, 19 or 18 in combination Etravirine Maraviroc Lopinavir and ritonavir or darunavir.21 In our study, the proportion of patients with two act